Kai-Syuan Psychiatric Hospital, China.
J Clin Psychopharmacol. 2012 Dec;32(6):773-7. doi: 10.1097/JCP.0b013e318270dfca.
Remission seems achievable for a portion of schizophrenic patients. This study aimed to identify the early predictors for remission and to establish an optimal prediction model. One hundred thirty-five acutely ill schizophrenic inpatients received 150-mg/d zotepine treatment for 4 weeks. Psychopathologic severity was assessed weekly using the Brief Psychiatric Rating Scale (BPRS). Symptomatic remission was defined according to the consensus criteria proposed by Andreasen et al. Backward stepwise logistic regression model was used to obtain the early predictors. The receiver operating characteristic curve was used to determine the cutoff point of predictors. The study was conducted from June 2004 to April 2005. Twenty-one (21.0%) of 100 completers remitted after 4 weeks of treatment. The most influential predictors for ultimate remission were percentage of BPRS score reduction at week 2 and BPRS remission-items score at week 2. Brief Psychiatric Rating Scale score reduction at week 2 of 35% and BPRS remission-items score of 18 at week 2 seemed to be the optimal cutoff points. They provided a sensitivity of 62% and 84% and a specificity of 86% and 65%. Patients with less than a 35% BPRS score reduction and a BPRS remission-items score larger than 18 during the first 2 weeks of treatment were unlikely to reach a final remission. Whether the finding can be extrapolated to other validated assessment scales and other antipsychotics require further studies.
部分精神分裂症患者似乎可以达到缓解。本研究旨在确定缓解的早期预测因素,并建立一个最佳的预测模型。135 名急性精神分裂症住院患者接受了为期 4 周的 150mg/d 佐替平治疗。每周使用简明精神病评定量表(BPRS)评估精神病理严重程度。根据 Andreasen 等人提出的共识标准定义症状缓解。采用向后逐步逻辑回归模型获得早期预测因素。使用受试者工作特征曲线确定预测因素的截断点。该研究于 2004 年 6 月至 2005 年 4 月进行。21 名(21.0%)100 名完成者在 4 周治疗后缓解。最终缓解的最主要预测因素是第 2 周 BPRS 评分降低的百分比和第 2 周 BPRS 缓解项目评分。第 2 周 BPRS 评分降低 35%和第 2 周 BPRS 缓解项目评分 18 似乎是最佳的截断点。它们提供了 62%和 84%的敏感性和 86%和 65%的特异性。在治疗的前 2 周内 BPRS 评分降低小于 35%和 BPRS 缓解项目评分大于 18 的患者不太可能达到最终缓解。该发现是否可以推广到其他经过验证的评估量表和其他抗精神病药物,需要进一步研究。